002019 Yifan Pharmaceutical
- 12.35
- -0.36-2.83%
Yifan Pharmaceutical News
Yifan Pharmaceutical (002019.SZ): Ginkgo leaf pill does not involve national talks.
According to Yifan Pharmaceutical (002019.SZ) on November 12th, the company stated on the investor interaction platform that the products involved in this national negotiation are Dipyridamole Oral Suspension, and Ginkgo Biloba Capsules are not part of the negotiation.
yifan pharmaceutical (002019.SZ): Currently not shipping to the usa market.
GeLonghui November 7th | yifan pharmaceutical (002019.SZ) stated on the investor interaction platform that no shipments are currently being made to the usa market.
yifan pharmaceutical (002019): significant increase in sales of own products, remarkable results in improving quality and efficiency.
On October 31, 2024, the company released the third quarterly report of 2024. The total operating income for the first three quarters of 2024 reached 3.858 billion yuan, a year-on-year increase of 31.67%; net income attributable to the parent company was 0.366 billion yuan, a year-on-year increase of 14.
Yifan Pharmaceutical (002019): Performance maintains a high-speed growth trend. Yilishu's delivery in Europe has made breakthroughs in global expansion again.
The company released its Q3 report for 2024. In the first three quarters of 2024, total operating income was 3.858 billion yuan, a year-on-year increase of 31.67%; net income attributable to the parent company was 0.366 billion yuan, a year-on-year increase of 149.5%, net income attributable to the parent company after non-recurring items.
yifan pharmaceutical (002019): yilishu overseas shipments Joint venture company announces TCE human data in SLE, worth looking forward to.
In the first three quarters of 2024, the company achieved revenue of 3.858 billion yuan, a year-on-year increase of 31.7%; net income attributable to the parent company was 0.366 billion yuan, a year-on-year increase of 150%; net income excluding non-recurring items was 0.252 billion yuan, a year-on-year increase of 122.
Yifan Pharmaceutical: Report for the third quarter of 2024
Yifan Pharmaceutical (002019.SZ): The net income for the first three quarters was 0.366 billion yuan, a year-on-year increase of 149.50%.
On October 30, Yifan Pharmaceutical (002019.SZ) announced its third quarter report for 2024, with the company achieving revenue of 3.858 billion yuan in the first three quarters, a year-on-year increase of 31.67%; net income attributable to shareholders of the listed company was 0.366 billion yuan, a year-on-year increase of 149.50%; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 0.252 billion yuan, a year-on-year increase of 122.30%; basic earnings per share were 0.30 yuan. The revenue increased by 31.67% compared to the same period last year, mainly due to the gradual approval and market launch of company-developed and imported pharmaceutical varieties, as well as the company's existing pharmaceutical inventory.
Express News | yifan pharmaceutical: Pimin Xiao Capsule has obtained regulatory approval in Singapore.
Yifan Pharmaceutical's Unit Gets Nod to Market Famotidine Injection
Express News | Yifan Pharmaceutical: Famotidine Injection Obtains Pharmaceutical Registration Certificate
Yifan Pharmaceutical (002019.SZ) interim equity distribution: 1 yuan per 10 shares.
yifan pharmaceutical (002019.SZ) announced that the company's 2024 interim equity distribution scheme is: to distribute equity to shareholders for half a year...
Yifan Pharmaceutical (002019.SZ): The company has not produced products for this indication (monkeypox).
Yifan Pharmaceutical (002019.SZ) stated on the investor interaction platform on August 31st that the company does not produce products for this indication (monkeypox); at the same time, kindly remind investors not to believe rumors, to rationally distinguish various types of information, and to pay attention to investment risks.
Yifan Pharmaceutical (002019): Performance meets expectations, achieving new breakthroughs in overseas business.
On August 15, 2024, the company released its 2024 interim report. In the first half of 2024, the company achieved revenue of 2.632 billion yuan, a year-on-year increase of 35.39%; and achieved a net income attributable to shareholders of 0.253 billion yuan, a year-on-year increase of 133.
Yifan Pharmaceutical (002019): Performance meets expectations, bullish on continued high growth in performance.
The company released its 2024 interim report, with revenue of 2.63 billion yuan (+35.4%) and net income attributable to the parent of 0.25 billion yuan (+133.0%) and non-net income of 0.18 billion yuan (+90.5%) for the first half of 2024. In the second quarter of 2024, revenue was 1.31 billion yuan (+29.9%), net income attributable to the parent was 0.11 billion yuan (+144.1%), and non-net income was 0.07 billion yuan (+102.0%).
Yifan pharmaceutical (002019): Rapid growth of proprietary pharmaceutical products, looking forward to the global commercialization progress of innovative drugs.
On August 15th, the company released its 2024 half-year report, achieving revenue of 2.623 billion yuan, a year-on-year increase of 35.39%, and a net income attributable to mother of 0.253 billion yuan, a year-on-year increase of 133.04%.
Yifan Pharmaceutical: Half-year report for the year 2024.
Yifan Pharmaceutical: Summary of Half-Year Report in 2024.
Yifan Pharmaceutical's H1 revenue and net profit both increased, and innovative drug Yilishu cumulative shipments exceeded 1.1 million units. | Interpretations
① Thanks to a sharp increase in domestic pharmaceutical product revenue and sales of vitamin B5 series products, H0.1 billion Pharm's revenue and net profit increased this year. ② The gross margin of APIs decreased year-on-year. Yifan Pharmaceutical said that the price of the company's vitamin B5 products is still running low. ③ The company's construction of the Hangzhou Synthetic Biology Industrial Park is being accelerated.
Express News | Yifan Pharmaceutical: Net income increased by 133.04% in the first half of 2024.
Express News | Delivery of some vitamin products from BASF has been affected by force majeure. Concept stocks have surged and over 10 listed companies have responded to their related business layout.
Analysis
Price Target
No Data
No Data